RLYB
Rallybio Corp
NASDAQ · Healthcare · Biotechnology · US
$15.90
+0.25%Margins
Gross margin
-742.9%
EBITDA margin
7190.6%
EBIT margin
-4659.2%
Net margin
6177.4%
FCF margin
7053.9%
29.0%
Return on equity
28.1%
Return on assets
-21.9%
Return on invested capital
0.00x
Asset turnover
$30.6M
Cash from operations
$17
Cash per share
Margins, returns on capital and operating efficiency from the latest trailing period · Data as of Sep 1, 2026